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Epidemiological data demonstrate a clear link between periodontal disease and diabetes, and 
individuals with diabetes, particularly if poorly controlled, are at risk for advanced periodontitis. 
Diabetes is increasingly viewed as an inflammatory condition and dysregulated immune-inflam-
matory responses in diabetes may increase susceptibility to periodontal disease by disrupting local 
cytokine networks in the periodontium. Inflammatory cytokines such as interleukin-6 (IL-6) and 
tumour necrosis factor-α (TNF-α) are important in the pathogenesis of both diseases, and together 
with other pro-inflammatory cytokines and adipokines, may provide a mechanistic link between 
the two diseases. Altered neutrophil function and deposition of advanced glycation end-products 
(AGEs) are also likely to be important in the increased susceptibility to periodontal disease seen in 
people with diabetes. Emerging data suggest that treating periodontal disease may have a beneficial 
effect on glycaemic control, and highlight the need to incorporate a full periodontal examination 
into management strategies for patients with diabetes. It is clear that the dental team must become 
increasingly involved in the management of patients with diabetes, and it is recommended that 
periodontal screening of all patients diagnosed with diabetes is undertaken as a matter of routine.
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It has long been recognised by the dental community 
that patients with diabetes have a greatly increased risk 
for periodontal disease. Patients with both type 1 
diabetes mellitus (T1DM) and type 2 diabetes mellitus 
(T2DM) often present with advanced periodontal dis-
ease, particularly if  they have poor glycaemic control. 
T1DM accounts for approximately 5% of  all cases of  
diabetes, and is mainly due to auto-immune destruction 
of  the β-cells in the pancreas. The precise aetiology is 
not fully understood, but may be triggered by viral infec-
tion. Destruction of  β-cells leads to reduced levels of  in-
sulin and resultant hyperglycaemia, and typically requires 
treatment with exogenous insulin. T2DM develops as 
a result of  both insulin resistance (i.e. an inability of  
the body to respond normally to insulin) and deficient 
β-cell function (resulting in failure to produce sufficient 
insulin). Onset of  T2DM was previously typically in 
middle age, but as a result of  high calorie food intake, 
obesity and sedentary lifestyles, younger individuals are 
now being diagnosed with T2DM. Early symptoms can 
be vague, however, and therefore many patients remain 
undiagnosed whereas others are diagnosed by chance 
during investigations for other conditions. T2DM is a 
heterogeneous condition and arises from interactions 
between environmental stressors (e.g. obesity, sedentary 
lifestyle) and genetic susceptibility that result in insulin 
resistance and the clinical manifestations of  disease.
In 2000, approximately 150 million people world-
wide were affected by T2DM, which is now regarded 
as a rapidly developing global epidemic predicted to 
affect approximately 300 million people by 20251. 
Prevention and management of  diabetes, particularly 
T2DM, and associated complications have become 
major healthcare challenges throughout the world. The 
emergence of  diabetes as a global epidemic is a recent 
phenomenon driven by the trends of  poor diet and a 
collapse in physical activity. These environmental stres-
sors unmask a genetic susceptibility, sometimes referred 
to as the ‘thrifty genotype’, to the disease. The thrifty 
gene hypothesis holds that certain genes have evolved 
to maximise metabolic efficiency, lipid storage and food 
searching behaviour to ensure survival during the peri-
ods of  starvation that would have regularly confronted 
our ancestors2. During such periods of  food shortage, 
those individuals who could store energy in the form 
of  lipid most efficiently would have had a survival ad-
vantage. However, in times of  abundance, these same 
genes predispose their carriers to diabetes as a result 
of  excessive nutritional intake and obesity. With the 
advent of  relative inactivity and high fat, high carbo-
hydrate and low fibre diets, this genotype is no longer 
advantageous because it is too efficient. This has led 
to obesity and related health problems throughout the 
world and is a clear example of  how our evolutionary 
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development has become mismatched from our present 
day environment. 
The complications of  diabetes stem from chronic 
hyperglycaemia, which has wide ranging molecular and 
cellular effects resulting in oxidative stress, upregulation 
of  pro-inflammatory responses and vascular changes. 
Collectively, these predispose individuals to the classic 
diabetes complications: retinopathy, nephropathy, neu-
ropathy, macrovascular disease (including atherosclero-
sis) and altered wound healing.
Diabetes and periodontal disease
Oral manifestations of  diabetes have been reported to 
include xerostomia, burning mouth syndrome, candidal 
infection, altered taste sensation, periodontal disease, 
dental caries and delayed wound healing3. As early as 
1993, periodontal disease was described as the 6th com-
plication of  diabetes4. However, it has taken many years 
for this to become more widely accepted. Indeed, only 
in 2003 did the American Diabetes Association’s Report 
of  the Expert Committee on Diabetes Diagnosis and 
Classification state that “Hypertension, abnormalities 
of  lipoprotein metabolism and periodontal disease are 
often found in people with diabetes”5.
The epidemiological links between T2DM and peri-
odontal disease are compelling and have been exten-
sively reviewed6. Some of  the earliest studies focussed 
on the Pima Indians, a population in the USA with a 
particularly high prevalence of  T2DM. Thus, in a study 
of  2,273 Pima Indians between 1983 and 1989, tooth 
loss and interproximal bone loss were used to define 
periodontal disease (the diagnosis of  periodontal disease 
was assigned if  <24 teeth were present, or there were ≥ 
6 teeth with ≥ 25% bone loss, or there were any teeth 
at all with ≥ 50% bone loss)7. The authors reported 
the prevalence of  periodontal disease to be 60% in the 
720 subjects with T2DM compared to 36% in 1,553 
controls7. These investigators also monitored those 
subjects with minimal or no periodontal disease at the 
initial screening (n=701) and identified the incidence 
(i.e. the onset of  new cases of  periodontal disease) to 
be 60 new cases per 1,000 person-years in the T2DM 
population and 17 new cases per 1,000 person-years in 
the control population. While we may criticise aspects 
of  the methodology in these early studies (e.g. the cri-
terion for ‘no periodontal disease’ permitted subjects to 
have up to 5 teeth with 25-50% bone loss and the rest 
of  the dentition to demonstrate up to 25% bone loss), 
they were among the first to establish the epidemiologi-
cal link between periodontal disease and T2DM.
In a further study of  359 Pima Indians, alveolar bone 
loss (up to 25% of  the root length) was identified in 67% 
of  21 T2DM patients compared to 44% of  338 non-
diabetic controls8. These individuals were monitored for 
a mean duration of  2.3 years (range 1.2-6.9 years) and it 
was noted that there was a significantly greater risk for 
ongoing bone loss (odds ratio 11.4; 95% CI: 2.5, 53.3; 
p<0.001) if  the diabetes was poorly controlled, but no 
significant risk for progressive bone loss (odds ratio 
2.2; 95% CI: 0.7, 6.5; not significant) if  diabetes was 
well controlled, compared to non-diabetic individuals. 
The threshold for defining good glycaemic control was 
glycated haemoglobin (HbA1c) < 9%. Interestingly, 
this study also provided evidence to support a possible 
negative effect of  periodontitis on glycaemic control, 
as subjects with moderate or well controlled T2DM 
at baseline who also had severe periodontitis were ap-
proximately six times more likely to have poor glycaemic 
control at 2 years post-baseline than the subjects who 
did not have severe periodontitis at baseline8.
In a study of  1,342 Pima Indians, the percentage of  
subjects with at least one periodontal site with attach-
ment loss ≥ 5mm was recorded9. For all age cohorts, 
the percentage of  individuals demonstrating this level 
of  periodontal disease was greater for those with T2DM 
compared to those without. These authors reported 
that individuals with T2DM had an increased risk for 
periodontal disease, with an odds ratio of  2.81 (95% CI 
1.91, 4.13) when attachment loss ≥ 5mm at one or more 
site was used to define the presence of  disease and an 
odds ratio of  3.43 (95% CI 2.28, 5.16) when bone loss 
≥ 25% at one or more site was used. 
Subsequent studies applied increasingly stringent 
classification criteria to define the presence or absence 
of  periodontal disease in an attempt to better confirm 
the association with diabetes. In a study of  102 T2DM 
patients and 102 age- and sex-matched controls in Swe-
den, bone loss ≥ 33% of  the root length was reported 
in 45% of  the T2DM patients compared to 28% of  
the controls (p=0.006)10. Furthermore, T2DM patients 
suffered more from xerostomia than controls (54% vs. 
28%, p=0.0003), and showed a greater need for peri-
odontal treatment (p=0.05), caries prevention (p=0.002) 
and prosthetic treatment (p=0.004). In a further study 
of  191 patients with T2DM in Sweden, 20% had peri-
odontal disease, defined as bone loss ≥ 33% of  the root 
length in ≥ 30% of  periodontal sites11. Those with a 
diagnosis of  periodontal disease had higher HbA1c 
than controls (7.1% vs. 6.5%, p=0.033) and higher 
prevalence of  cardiovascular complications (25% vs. 
4%, p=0.012).
When considering type 1 diabetes, a trend towards 
more alveolar bone destruction was seen in 35 adults 
aged 24-36 years with increasing severity of  diabetes 
(determined from HbA1c values and the presence of  
diabetes complications such as retinopathy)12. In a large 
study of  350 children aged 6-18 years old (of  whom 
325 had T1DM) and 250 non-diabetic controls, sub-
jects with diabetes had increased gingival inflammation 
and attachment loss compared to the controls13. In this 
study, 21% of  sites in the patients with diabetes had at-
tachment loss > 2mm compared to 8% in the controls 
(p<0.001). Thus, it is clear that even at an early age, 
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diabetes increases the risk for periodontal destruction. 
These authors recommended that strategies to address 
periodontal treatment need should be implemented and 
become standard of  care even in young children with 
diabetes.
It is clear from a large number of  studies that diabe-
tes (both T1DM and T2DM) is a significant risk factor 
for periodontal disease, and the risk is greater if  glycae-
mic control is poor. The next challenge is to understand 
why diabetes, especially if  poorly controlled, has such 
an impact on periodontal health.
Mechanisms linking diabetes and periodontal 
disease
Periodontitis and diabetes share common pathogenic 
processes and both can be thought of  as upregulated 
and/or maladapted responses of  the immune system 
to environmental stressors acting on the host. In the 
case of  periodontitis, susceptible individuals mount an 
aggressive, upregulated inflammatory response to the 
presence of  plaque, with environmental stressors (e.g. 
smoking) adversely affecting the disease process14. En-
vironmental stressors in T2DM include excessive food 
intake, lack of  exercise and obesity, and these combine 
with a genetic susceptibility to result in the signs and 
symptoms of  diabetes.
The inflammatory response in the periodontal tissues 
is characterised by the local production of  a variety of  
inflammatory mediators and enzymes, such as cytokines 
(e.g. interleukins), prostanoids, and matrix metallopro-
teinases (MMPs). Inappropriate cytokine secretion, 
whether quantitative (i.e. excessive cytokine release) 
and/or qualitative (e.g. an imbalance between the pro-
portions of  pro- and anti-inflammatory cytokines) is 
a manifestation of  dysregulated immune responses 
and results in periodontal tissue destruction. As the 
inflammatory front induced by the subgingival biofilm 
extends laterally and apically, infiltrating cells such as 
polymorphonuclear leukocytes (PMNL), monocytes/
macrophages and lymphocytes are recruited to the area, 
occupying a considerable volume of  the soft tissues. As 
the inflammatory infiltrate extends towards the alveolar 
bone, osteoclastic bone resorption is enhanced so the 
bone retreats from the expanding area of  inflammation. 
Key cytokines that drive these processes include inter-
leukin-1 (IL-1) and tumour necrosis factor-α (TNF-α), 
and local over-production of  these cytokines is a major 
contributor to periodontal breakdown. Local networks 
of  a range of  both pro- and anti-inflammatory cytokines 
are critical in determining the extent of  tissue destruc-
tion, and it is reasonable to assume that substantial 
changes in immunologically active molecules as a result 
of  systemic disease (e.g. diabetes) might disturb finely 
balanced cytokine networks in the periodontium. This 
could alter local inflammatory responses and increase 
the susceptibility to periodontal disease in people with 
diabetes. The hypothesis that diabetes alters local in-
flammatory networks in the periodontium, and that this 
may explain the increased susceptibility to periodontal 
disease, is strengthened by the concept of  diabetes as 
an inflammatory condition.
T2DM is an inflammatory condition
T2DM is increasingly viewed as an inflammatory condi-
tion. Thus, the development of  T2DM is preceded by a 
low grade systemic inflammation15. Plasma concentra-
tions of  IL-6 and TNF-α are increased in obesity and 
T2DM16. Hyperglycaemia results in cellular oxidative 
stress and resultant inflammatory changes. The source 
of  TNF-α in the serum of  T2DM patients is partly from 
adipose tissue, and also from stimulation of  leukocytes 
by advanced glycation end-products (AGEs – see be-
low). Increased circulating IL-6 is also associated with 
insulin resistance and may predict future T2DM17.
Although adipose tissue has previously been con-
sidered a passive store of  lipid, it is now regarded as 
an active endocrine organ that secretes a wide range of  
immunologically active molecules involved in regulating 
food consumption and energy balance18. These mol-
ecules are collectively known as adipokines, and include 
leptin, adiponectin, resistin and visfatin. Leptin activates 
inflammatory responses by acting as an acute-phase 
reactant and a stimulator of  neutrophil function, and 
it can also stimulate cytokine secretion by monocytes19. 
Leptin levels directly correlate with adipose tissue mass, 
and act to decrease food intake and increase energy 
consumption20. Obese individuals have increased cir-
culating levels of  leptin and increased resistance to its 
actions in the control of  food intake21. High leptin levels 
have been associated with increased risk of  developing 
T2DM22. Leptin has also been identified in the gingiva 
in concentrations that inversely correlate with probing 
depths23. Further details on the potential roles of  leptin 
and other adipokines in periodontal pathogenesis have 
been reviewed elsewhere24.
TNF-α and C-reactive protein (CRP) are also pro-
duced by adipose tissue and thus can be considered adi-
pokines. There are clear associations between elevated 
serum TNF-α levels and obesity. CRP is synthesised 
in the liver and also by adipocytes25. CRP production 
is regulated primarily by circulating IL-6 levels, and 
therefore is influenced by adipocytes which themselves 
secrete significant quantities of  IL-6. CRP levels are 
elevated in obesity and T2DM, and elevated CRP levels 
have been associated with periodontitis26. The associa-
tion of  elevated systemic CRP levels with periodontal 
disease and subsequent decreases following periodontal 
therapy27 are taken to indicate that the inflammatory 
response to periodontitis contributes to the overall in-
flammatory challenge throughout the body. However, 
the precise role of  CRP in linking periodontal disease 
and diabetes remains unclear.
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We can conclude that relationships between cytokine 
networks in the periodontium and T2DM are likely to 
be complex. Emerging research supports a contributory 
role for circulating inflammatory cytokines in insulin 
resistance and for upregulated inflammatory responses 
in the periodontium in the presence of  hyperglycaemia. 
Thus, a trend for increasing GCF IL-1β concentrations 
has been identified as diabetes control decreases28. Fur-
thermore, poorly controlled T2DM patients (HbA1c 
> 8.0%) with untreated periodontitis have significantly 
higher GCF IL-1β levels compared to T2DM patients 
with moderate or good glycaemic control29. More re-
cently, in a study of  10 T2DM patients and 10 controls, 
GCF IL-1β levels were nearly twice as high in those with 
diabetes compared to the controls (though this did not 
reach statistical significance)30. Thus, individuals with 
diabetes, particularly those with poor glycaemic control, 
can be considered to mount upregulated immune-in-
flammatory responses against the subgingival biofilm, 
resulting in increased tissue damage and the clinical signs 
of  disease. Dysregulation of  cytokine networks may 
underpin a wide range of  systemic disorders and may 
provide the basis for cross-susceptibility between dia-
betes and periodontal disease24. Furthermore, research 
supports a contributory role for circulating cytokines 
(which may, in part, be derived from the inflamed peri-
odontium) in insulin resistance. For example, binding 
of  TNF-α and IL-6 to receptors in muscle cells or 
hepatocytes can directly interfere with insulin signal-
ling and consequently dampen the cellular response to 
insulin31,32. 
Impaired PMNL function
Impaired function of  PMNL may be a further mecha-
nistic link between periodontal disease and diabetes. 
T2DM has been shown to result in impaired PMNL 
chemotaxis33, adherence34 and phagocytosis35. Further-
more, diabetic patients with severe periodontitis have 
been shown to have depressed PMNL chemotaxis 
compared to non-diabetics with periodontitis or diabet-
ics with mild periodontitis36,37. Diabetes may also result 
in increased susceptibility to periodontal disease via 
impaired PMNL apoptosis (programmed cell death)38. 
Patients with diabetes have been reported to have de-
fective PMNL apoptosis39, which may in turn lead to 
increased retention of  PMNLs in the periodontium 
resulting in increased tissue destruction by continued 
release of  MMPs and reactive oxygen species.
Advanced glycation end-products
In the hyperglycaemic state, proteins and matrix mol-
ecules undergo non-enzymatic glycosylation resulting 
in the formation of  AGEs. This occurs in people who 
do not have diabetes too, but in the hyperglycaemic 
state formation of  AGEs is excessive. Collagen be-
comes cross-linked by AGE formation, making it less 
soluble and less amenable to appropriate remodelling. 
Cellular migration through these tissues is impeded 
and tissue integrity is impaired. There is evidence that 
AGEs play a role in periodontal pathogenesis via their 
interaction with the cellular AGE receptor (RAGE) 
present on monocytes and macrophages40. Binding of  
AGE to RAGE results in upregulation of  inflamma-
tory cytokines such as IL-1β, IL-6 and TNF-α41 and 
monocytes from patients with diabetes produce greater 
quantities of  cytokines in vitro compared to non-diabetic 
controls42. 
AGE formation also results in the production of  
reactive oxygen species (ROS) and enhances oxidant 
stress. The subsequent endothelial cell changes that oc-
cur contribute to the vascular injury that is implicated in 
many diabetes complications43. AGEs also enhance the 
respiratory burst in neutrophils44 which may significantly 
increase local tissue damage in the periodontium. 
Thus, there are several mechanisms that are likely to 
play a role in the increased susceptibility to periodontal 
disease observed in people with diabetes. Susceptible 
individuals are considered to mount excessive, dysregu-
lated inflammatory responses to the presence of  plaque 
bacteria, and this is exacerbated in diabetes. Figure 1 
presents a model for the increased periodontal destruc-
tion observed in diabetes.
Impact of periodontal treatment on diabetes
A small number of  studies have investigated whether 
effective periodontal treatment can improve diabetes 
control. Most have been somewhat under-powered and 
of  varying designs, particularly with respect to the peri-
odontal treatment provided. It is therefore difficult to 
draw clear conclusions as to the impact of  periodontal 
therapy on glycaemic control. In a meta-analysis of  
10 intervention studies to quantify the effects of  peri-
odontal therapy on HbA1c, a weighted mean absolute 
decrease in HbA1c of  0.66% was observed in T2DM 
patients following periodontal treatment, though this did 
not achieve statistical significance45. However, this sug-
gests that there is a possibility that periodontal therapy 
may have an impact on diabetes control, but this remains 
to be confirmed in larger studies. 
Future recommendations
In the latter part of  the 20th century, the reported preva-
lence of  advanced periodontitis in Western populations 
reduced from approximately 70%46 to approximately 
8-15%47,48. Partly these decreases are artificial, result-
ing from the changes in methodology (e.g. diagnostic 
techniques and thresholds for defining periodontal 
disease) that have occurred over time. However, there is 
no doubt that these decreases have also arisen because 
of  better awareness of  the importance of  oral hygiene 
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and improved diagnostics and management. Taking all 
these factors into consideration, it has been estimated 
that the incidence of  advanced periodontitis truly de-
creased by 31% from 1955 to 200049. One of  the most 
significant contributors to this is likely to have been the 
decrease in smoking that occurred over the same time 
period. Indeed, Hujoel and colleagues suggested that 
“a periodontitis epidemic fuelled by smoking remained hidden 
for much of  the 20th century. Because this epidemic was hidden, 
it distorted our understanding of  the treatment and etiology of  
periodontitis.” 
This decrease in the incidence in periodontal disease 
is to be welcomed. However, it is possible that we may 
now be at another turning point in the epidemiology 
of  periodontitis, and this is because of  the predicted 
increases in the prevalence of  diabetes that will oc-
cur over the next 25 years. As has become very clear, 
diabetes is a major risk factor for periodontal disease, 
and it is possible that, following a period of  decreasing 
prevalence of  periodontitis in recent decades (associated 
with less smoking and better oral health behaviours), we 
may now be about to commence a period of  increasing 
prevalence of  periodontitis (associated with obesity and 
diabetes). 
As dentists, we must remain alert to this possibility, 
and several recommendations for the future can be 
made.
• Careful oral and periodontal examination must be 
performed in all patients with diabetes, even in chil-
dren
• We must be aware of  the changing demographics of  
diabetes (and thus the increased risk for periodontal 
disease). Diabetes is increasingly common in emerg-
ing economies, and also in deprived segments of  
more affluent countries50-52 
Figure 1.  Mechanisms of increased susceptibility to periodontal disease in diabetes The hyperglycaemic state results in deposition 
of advanced glycation end-products (AGEs) throughout the body, including the periodontal tissues. Binding of the receptor for AGE 
(RAGE) on macrophages results in local cytokine release and altered inflammatory responses. Neutrophil function is also altered in 
the diabetic state, resulting in impaired neutrophil apoptosis and enhancement of the respiratory burst. Excess adipose tissue results 
in the release of cytokines such as tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6), and other adipokines. Local production 
of cytokines in the periodontal tissues may, in turn, affect glycaemic control through systemic exposure and an impact on insulin 
signalling. All of these factors contribute to dysregulated inflammatory responses that develop in the periodontal tissues in response to 
subgingival plaque bacteria. This results in excessive production of inflammatory cytokines such as IL-1β and TNF-α and destructive 
enzymes such as matrix metalloproteinases (MMPs), leading to collagen breakdown, osteoclastic bone resorption, and the clinical 
signs of periodontal disease.
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• We must liaise with our medical colleagues to become 
an integral part of  the healthcare team managing 
patients with diabetes
• Early diagnosis and prevention of  periodontal dis-
ease are of  fundamental importance in people with 
diabetes
• The entire dental team, together with our medical 
colleagues, have a role in educating patients to main-
tain periodontal health
• Periodontal screening of  all patients diagnosed with 
diabetes must become routine.
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